Receptor mechanisms of PAF mediated lymphatic constriction in the canine forelimb
| Autor: | Dobbins De |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1992 |
| Předmět: |
Pathology
medicine.medical_specialty medicine.drug_class Immunology Vascular permeability Pharmacology Constriction chemistry.chemical_compound Phentolamine Lymphatic vessel lcsh:Pathology Medicine Receptor Platelet-activating factor business.industry Cell Biology respiratory system Receptor antagonist Lymphatic system medicine.anatomical_structure chemistry lipids (amino acids peptides and proteins) business Research Article medicine.drug lcsh:RB1-214 |
| Zdroj: | Mediators of Inflammation, Vol 1, Iss 6, Pp 391-395 (1992) Mediators of Inflammation |
| ISSN: | 1466-1861 0962-9351 |
| Popis: | Platelet activating factor (PAF) is a potent inflammatory lipid. In this study we assessed the ability of PAF to impact lymphatic vessel function by altering prenodal lymphatic resistance. Intralymphatic PAF (7.47 × 10−6, 7.47 × 10−5and 7.47 × 10−4M) increased lymphatic perfusion pressure at the two highest infusion rates. PAF mediated lymphatic constriction was not altered by the intra-arterial infusion of phentolamine but was blocked by the intra-arterial infusion of the PAF receptor antagonist WEB 2170. These data indicate that in addition to PAF's effects on microvascular permeability, this agent may also impact the ability of the lymphatics to transport fluid through alterations in lymphatic smooth muscle tone. PAF mediated lymphatic constriction is not mediated by α-receptors but rather through PAF receptor mediated mechanism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text